conference reports
Temsirolimus and bevacizumab combi in metastatic RCC: TORAVA trial
Wednesday, 2 June 2010- Temsirolimus (T) and bevacizumab (B) have been approved for the treatment of metastatic renal cell carcinoma (mRCC). The T-B combination has proven feasible at full doses of each agent with promising...
Edited by: JV
Robot-assisted laparoscopic partial nephrectomy: a feasible option for patients
Thursday, 29 April 2010- Laparoscopic partial nephrectomy (LPN) has established a place as a minimal invasive, nephron sparing treatment for T1 renal tumours. In a poster session at the recently concluded 25th Anniversary EAU...
Edited by: JV
Preliminary experience with sorafenib and cytoreductive nephrectomy in mRCC
Wednesday, 28 April 2010- The role of cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) in the targeted therapy era is unknown and is being addressed in randomised trials.
A.Finelli and colleagues...
Edited by: JV
Surgery plays a major role even in patients with mRCC
Sunday, 18 April 2010- Surgery plays a major role in patients with metastatic renal cell carcinoma (mRCC) despite the development of new drugs known as 'targeted therapies,' said Prof. Ziya Kirkali during a course on surgery and...
Edited by Joel Vega
EAU Congress: plenary session tackles medical therapy for advanced cancer
Saturday, 17 April 2010- Advances in the management of kidney cancer were taken in a case discussion with experts saying that surgery still plays a major role in metastatic renal cell carcinoma (mRCC) despite the recent entry of...
By Joel Vega
Hospitalistion after renal ablation unecessary
Thursday, 8 April 2010- Ablation of renal masses can be performed routinely as outpatient procedures and usually do not require hospital admission for post-procedure observation, researchers reported here at the Society of...
Edited by: ES
Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma
Monday, 5 April 2010- Sunitinib is a front-line standard of care in patients with metastatic renal cell carcinoma (mRCC). Patients who progress during treatment with sunitinib typically are treated with multiple sequential...
Edited by: JV
Cytoreductive nephrectomy in mRCC patients treated with VEGF-targeted therapy
Tuesday, 30 March 2010- VEGF-targeted therapy is the standard of care in patients with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) is a standard of care as defined in the cytokine era, although not...
Edited by: JV
Sequential use of temsirolimus in mRCC patients after failed TKI treatment
Thursday, 25 March 2010- Agents targeting the mTOR pathway may provide clinical benefit in pre-treated metastatic renal cell carcinoma (mRCC) patients, but data from prospective randomised trials on the sequential use of...
Edited by: JV
Phase 3 AVOREN trial: OS improvement in mRCC patients given bevacizumab and interferon
Wednesday, 17 March 2010- Bevacizumab (BEV) plus interferon (IFN) is an active first-line treatment option for patients (pts) with metastatic renal cell carcinoma (mRCC), demonstrated to significantly improve median...
Edited by: JV
